Application of Hippo signal channel blocker in preparation of anti-ER + breast tumor medicine
A signaling pathway, breast tumor technology, applied in the field of anti-tumor drugs to achieve the effect of improving drug resistance
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0085] Expression and prognosis of YAP in ER+ breast cancer
[0086] 1. Progression-free survival data analysis
[0087] The progression-free survival (PFS) survival data of YAP were obtained from KMPLOT online analysis database (http: / / kmplot.com / analysis / index.php?p=service&cancer=breast). The gene affyID is 224894_at. Select "Automatically Selected Best Cutoff" and "ER Positive" for ER-positive breast cancer analysis. "Auto-selected optimal cutoff" and "ER-negative" were selected for ER-negative breast cancer analysis.
[0088] PFS survival data for TEAD4 in endocrine therapy patients were obtained from the KMPLOT database. The gene affyID is 41037_at. Select "Automatically select best cutoff" and "Endocrine treated patients" for analysis. The PFS survival data of MST1(STK4), MST2(STK3) and TAZ(WWTR1) in endocrine therapy patients were obtained from KMPLOT database. Gene association IDs are 225364(MST1), 204068(MST2) and 202133(TAZ)_at. Select "Automatically select b...
Embodiment 2
[0097] Inhibition of MST1 / 2 or activation of YAP blocks the growth of ER+ breast cancer cells
[0098] To determine whether increasing YAP activity could suppress the growth of ER+ breast cancer cells, we utilized a pharmacological small molecule inhibitor, XMU-MP-1, which specifically inhibits the activity of the kinase MST1 / 2, thereby promoting YAP nuclear localization and activation.
[0099] It was found that XMU-MP-1 inhibited the growth of ER+ breast cancer cell lines including MCF-7 and T47D in a dose-dependent manner ( Figure 7-8 ). Immunostaining or fractionation of MCF-7 cells treated with XMU-MP-1 showed increased nuclear localization of YAP ( Figure 9 ). Furthermore, the inhibitory effect of XMU-MP-1 on the growth of MCF-7 cells was partially reversed by siRNA-mediated YAP knockdown (KD) ( Figure 10 ), indicating that MST1 / 2 inhibition blocks the growth of ER+ breast cancer cells through YAP.
[0100] Consistent with the notion that YAP activation suppresse...
Embodiment 3
[0102] Inhibition of Hippo signaling pathway or activation of YAP inhibits ER+ breast cancer progression in xenograft tumor models
[0103] 1. Daily injection of XMU-MP-1 in estrogen-supplemented female NODscidγ (NSG) mice for 3 weeks significantly inhibited tumor growth compared with control treatment ( Figure 13 ), indicating that MST1 / 2 inhibition can reduce the growth of ER+ breast cancers in vivo.
[0104] 2. We also generated MCF-7 cell lines stably expressing inducible YAP-5SA (Tet-O-YAP-5SA) or its TEAD-binding-deficient form (Tet-O-YAP-5SAS94A), and derived cells carrying these line of xenografts. Mice were injected daily intraperitoneally with Dox (20 mg / kg) in PBS or PBS for the indicated time periods. Dox-induced expression of YAP-5SA significantly reduced tumor growth, whereas expression of YAP-5SAS94A had no effect ( Figure 14 ), indicating that YAP activation suppresses the growth of ER+ breast cancers in vivo and does so by binding to TEAD.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


